恩扎卢胺联合或不联合亮丙瑞林治疗高危生化复发前列腺癌:EMBARK试验年龄亚组事后分析
EMBARK试验事后分析按年龄(<70岁 vs ≥70岁)分层,评估恩扎卢胺联合或不联合亮丙瑞林治疗高危生化复发非转移性去势敏感性前列腺癌的疗效与安全性。结果显示,无论年龄,联合组和单药组均较单用亮丙瑞林改善无转移生存(MFS);≥70岁患者治疗相关严重不良事件(TRSAEs)和≥3级不良事件更常见,但TRSAEs总体较低。
要点
- 无论年龄,恩扎卢胺联合或不联合亮丙瑞林均较单用亮丙瑞林改善MFS。
- ≥70岁患者TRSAEs和≥3级AEs发生率高于<70岁患者,但TRSAEs总体较低。
- 亚组样本量较小,结果需谨慎解读。
核心结论
- 在高危生化复发前列腺癌患者中,无论年龄,恩扎卢胺联合或不联合亮丙瑞林均观察到具有临床意义的MFS改善。
- ≥70岁患者TRSAEs更常见,但各年龄组TRSAEs发生率均较低。
研究设计与样本
- EMBARK试验(NCT02319837)事后分析,纳入1068例高危生化复发非转移性去势敏感性前列腺癌患者。
- 患者随机(1:1:1)接受恩扎卢胺联合亮丙瑞林、亮丙瑞林联合安慰剂或恩扎卢胺单药治疗。
- 按年龄(<70岁 vs ≥70岁)分层比较MFS和安全性结局。
主要发现
- 1068例患者中,543例(51%)<70岁,525例(49%)≥70岁。
- ≥70岁患者在各治疗组中基线PSA中位值更高,既往接受原发放疗的比例更高。
- 无论年龄,联合组和单药组较亮丙瑞林单用组均观察到MFS改善。
- TRSAEs发生率范围为0.6-11.7%,≥3级AEs发生率范围为36.3-60.1%。
关键数值与推荐
- 入组条件:局部治疗后高危生化复发,PSA倍增时间≤9个月,放疗后PSA≥2 ng/mL高于最低点或根治性前列腺切除术后±术后放疗PSA≥1 ng/mL。
- 年龄分组:<70岁 vs ≥70岁。
临床怎么用
- 对于高危生化复发前列腺癌患者,年龄不应作为排除恩扎卢胺联合或不联合亮丙瑞林治疗的唯一依据。
- ≥70岁患者治疗期间应加强不良事件监测,尤其是严重不良事件和≥3级不良事件。
局限性
- 事后分析,亚组样本量较小,结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The EMBARK trial demonstrated that enzalutamide ± leuprolide significantly improved metastasis-free survival (MFS) in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence (hrBCR). This post hoc analysis reports the efficacy and safety results when patients were stratified by age. METHODS: The EMBARK trial (NCT02319837) included patients with hrBCR after local therapy, prostate-specific antigen (PSA) doubling time ≤ 9 months, and PSA ≥ 2 ng/mL above nadir post radiotherapy (RT) or ≥ 1 ng/mL after radical prostatectomy ± postoperative RT. Patients were randomized (1:1:1) to enzalutamide with leuprolide (combination), leuprolide and placebo (leuprolide alone), or enzalutamide alone (monotherapy). This analysis compares MFS and safety outcomes by age group (<70 vs ≥70 years). RESULTS: Of 1068 patients, 543 (51 %) were aged < 70 years and 525 (49 %) were aged ≥ 70 years. Patients ≥ 70 years had higher median baseline PSA and higher rates of primary RT versus patients < 70 years across all treatment groups. Improvements in MFS were observed in the combination and monotherapy groups compared with leuprolide alone, regardless of age. Treatment-related serious adverse events (TRSAEs) and grade ≥ 3 AEs were more common in patients aged ≥ 70 years versus < 70 years for all treatment groups, but TRSAEs were low in all treatment and age groups (TRSAEs: 0.6-11.7 %; grade ≥3 AEs: 36.3-60.1 %). CONCLUSION: Clinically meaningful improvements in MFS were observed following enzalutamide ± leuprolide in patients with hrBCR regardless of age. TRSAEs were more common in older patients but were low regardless of age. These findings should be interpreted in light of small subgroup sizes.
引用
- Shore ND, De Giorgi U, Kalac M, et al. Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by age. Eur J Cancer. 2025. PMID: 41274168. doi:10.1016/j.ejca.2025.116110
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。